Indoleamine 2,3-dioxygenase (IDO1) catalyzes the first step in tryptophan breakdown along the kynurenine pathway. Therapeutic inhibition of IDO1 is receiving much attention due to its proposed role in the pathogenesis of several diseases including cancer, hypotension and neurodegenerative disorders. A related enzyme, IDO2 has recently been described. We report the first purification and kinetic characterization of human IDO2 using a facile l-tryptophan consumption assay amenable to high throughput screening. We found that the K(m) of human IDO2 for l-tryptophan is much higher than that of IDO1. We also describe the identification and characterization of a new IDO1 inhibitor compound, Amg-1, by high throughput screening, and compare the inhibition profiles of IDO1 and IDO2 with Amg-1 and previously described compounds. Our data indicate that human IDO1 and IDO2 have different kinetic parameters and different inhibition profiles. Docking of Amg-1 and related analogs to the known structure of IDO1 and to homology-modeled IDO2 suggests possible rationales for the different inhibition profiles of IDO1 and IDO2.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbapap.2011.07.023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gene Variant Frequencies of , , , and in Substance Use Disorder Cohorts.
Genes (Basel)
October 2024
Luxor Scientific, LLC, 1327 Miller Rd., Greenville, SC 29607, USA.
Article Synopsis
- Substance use disorder (SUD) is a major public health issue in the U.S., linked to rising overdose deaths and prescription drug misuse, highlighting the need to explore its molecular and genetic roots.
- The study utilized the All of Us cohort to analyze genetic variants in four genes related to the kynurenine pathway across six groups, including various types of substance use disorders.
- Results indicated significant genetic variations in 14 out of 18 polymorphisms, with the cocaine group showing the highest number of significant variants, suggesting possible genetic predictors for increased susceptibility to SUD.
The Two Sides of Indoleamine 2,3-Dioxygenase 2 (IDO2).
Cells
November 2024
Section of Pharmacology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy.
Indoleamine 2,3-dioxygenase 1 () and originated from gene duplication before vertebrate divergence. While IDO1 has a well-defined role in immune regulation, the biological role of IDO2 remains unclear. Discovered in 2007, is located near the gene.
View Article and Find Full Text PDFGene expression of kynurenine pathway enzymes in depression and following electroconvulsive therapy.
Acta Neuropsychiatr
October 2024
Neuropsychopharmacology Research Group, School of Pharmacy and Pharmaceutical Sciences & Trinity College Institute of Neuroscience, Trinity College, Dublin, Ireland.
Article Synopsis
- This study explored how the expression of kynurenine pathway (KP) enzymes in the blood is affected in patients with depression compared to healthy controls and post-electroconvulsive therapy (ECT).
- Results showed that certain KP enzymes were lower in patients with depression, but these findings weren’t statistically significant after accounting for other factors; ECT didn't change KP enzyme expression.
- The study suggests that further research is needed to see if KP measures can effectively help in diagnosing depression and predicting responses to antidepressant treatments.
Neuroactive Kynurenines as Pharmacological Targets: New Experimental Tools and Exciting Therapeutic Opportunities.
Pharmacol Rev
October 2024
Department of Pharmacology, Physiology, and Neuroscience, University of South Carolina School of Medicine, Columbia, South Carolina (A.P.); Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, Maryland (R.S.); and Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (S.E.)
Both preclinical and clinical studies implicate functional impairments of several neuroactive metabolites of the kynurenine pathway (KP), the major degradative cascade of the essential amino acid tryptophan in mammals, in the pathophysiology of neurologic and psychiatric diseases. A number of KP enzymes, such as tryptophan 2,3-dioxygenase (TDO2), indoleamine 2,3-dioxygenases (IDO1 and IDO2), kynurenine aminotransferases (KATs), kynurenine 3-monooxygenase (KMO), 3-hydroxyanthranilic acid oxygenase (3-HAO), and quinolinic acid phosphoribosyltransferase (QPRT), control brain KP metabolism in health and disease and are therefore increasingly considered to be promising targets for the treatment of disorders of the nervous system. Understanding the distribution, cellular expression, and regulation of KP enzymes and KP metabolites in the brain is therefore critical for the conceptualization and implementation of successful therapeutic strategies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!